Globe Life Inc. $GL Shares Sold by Nuance Investments LLC

Nuance Investments LLC lessened its holdings in Globe Life Inc. (NYSE:GL) by 11.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 231,637 shares of the company’s stock after selling 28,581 shares during the quarter. Globe Life comprises about 3.6% of Nuance Investments LLC’s investment portfolio, making the stock its 10th largest position. Nuance Investments LLC’s holdings in Globe Life were worth $32,397,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Parallel Advisors LLC boosted its position in shares of Globe Life by 5.6% in the fourth quarter. Parallel Advisors LLC now owns 1,651 shares of the company’s stock worth $231,000 after buying an additional 87 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of Globe Life by 0.7% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 60,930 shares of the company’s stock worth $8,522,000 after buying an additional 430 shares during the period. Prudential PLC acquired a new stake in shares of Globe Life in the fourth quarter worth $1,429,000. Westfield Capital Management Co. LP boosted its position in shares of Globe Life by 41.4% in the fourth quarter. Westfield Capital Management Co. LP now owns 608,813 shares of the company’s stock worth $85,149,000 after buying an additional 178,171 shares during the period. Finally, CIBC Asset Management Inc boosted its position in shares of Globe Life by 65.7% in the fourth quarter. CIBC Asset Management Inc now owns 18,126 shares of the company’s stock worth $2,535,000 after buying an additional 7,186 shares during the period. Institutional investors and hedge funds own 81.61% of the company’s stock.

Globe Life Price Performance

Shares of NYSE:GL opened at $159.28 on Friday. Globe Life Inc. has a fifty-two week low of $116.73 and a fifty-two week high of $159.36. The business has a 50-day moving average of $150.46 and a two-hundred day moving average of $143.44. The stock has a market capitalization of $12.37 billion, a P/E ratio of 11.02 and a beta of 0.49. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.07 and a quick ratio of 0.07.

Globe Life (NYSE:GL) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $3.43 earnings per share for the quarter, missing analysts’ consensus estimates of $3.46 by ($0.03). Globe Life had a return on equity of 20.94% and a net margin of 19.38%.The company had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the firm earned $3.07 EPS. Globe Life’s quarterly revenue was up 5.3% on a year-over-year basis. Globe Life has set its FY 2026 guidance at 15.400-15.90 EPS. On average, equities research analysts predict that Globe Life Inc. will post 15.62 EPS for the current fiscal year.

Globe Life Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Monday, July 6th will be given a $0.33 dividend. The ex-dividend date of this dividend is Monday, July 6th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 0.8%. Globe Life’s payout ratio is currently 9.13%.

Wall Street Analyst Weigh In

GL has been the subject of several recent analyst reports. Evercore set a $157.00 target price on Globe Life in a research report on Wednesday, February 18th. Morgan Stanley lifted their price objective on Globe Life from $176.00 to $181.00 and gave the company an “overweight” rating in a research report on Thursday, May 21st. Keefe, Bruyette & Woods reissued a “moderate buy” rating and set a $168.00 price objective on shares of Globe Life in a research report on Thursday, March 26th. Wells Fargo & Company lifted their price objective on Globe Life from $171.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Finally, Weiss Ratings raised Globe Life from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Globe Life has an average rating of “Moderate Buy” and an average target price of $174.11.

Insider Buying and Selling

In other Globe Life news, CEO Frank M. Svoboda sold 20,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $156.68, for a total value of $3,133,600.00. Following the completion of the sale, the chief executive officer owned 54,020 shares of the company’s stock, valued at $8,463,853.60. The trade was a 27.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James Matthew Darden sold 4,663 shares of the business’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $153.88, for a total value of $717,542.44. Following the completion of the sale, the chief executive officer directly owned 58,451 shares of the company’s stock, valued at $8,994,439.88. This represents a 7.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 105,929 shares of company stock worth $16,382,450 over the last ninety days. 2.11% of the stock is currently owned by corporate insiders.

Globe Life Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.